Serum Levels of IL-27 and IL-30 as Predictor of Disease Activity and Treatment Response in Patients with Rheumatoid Arthritis: A Case-Control Study
DOI:
https://doi.org/10.54133/ajms.v7i2.1449Keywords:
Anti-CCP antibody, Etanercept, IL-27, IL-30, Methotrexate, Rheumatoid arthritisAbstract
Background: Most individuals with inflammatory arthritis are diagnosed with rheumatoid arthritis (RA), an immunological disorder characterized by autoantibodies, particularly anti-cyclic citrullinated peptide antibodies (ACCP), which initiate inflammatory responses. Recent studies have shown that cytokines contribute to the progression and dissemination of RA, with elevated levels of serum IL-27 and IL-30. Objective: To assess the utility of serum IL-27 and IL-30 levels as predictors of disease activity in RA patients and their correlation with response to treatment. Methods: One hundred patients and fifty healthy controls made up the total number of participants in this case-control research. Baghdad Teaching Hospital conducted the study from November 2023 to February 2024. The American College of Rheumatology 2010 criteria were used for patient recruitment. An ELISA technique was used to evaluate the amounts of the biomarkers. Results: The levels of IL-27 and IL-30 are significantly higher in rheumatoid arthritis patients compared to healthy controls. The mean serum IL-27 and IL-30 concentrations were highest in the severe, followed by moderate and low disease activity. Patients taking methotrexate had higher serum IL-27 and IL-30 concentrations, which were significantly higher than those on both etanercept and etanercept + methotrexate groups. Conclusions: Elevated serum levels of IL-27 and IL-30 may serve as diagnostic markers for RA and as indicators of disease activity and response to treatment.
Downloads
References
Al-Rubaye MR. Anti-neutrophlic cytoplasmic antibody elastase, lactoferrin, cathapsin G, and lysozyme in a sample of Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2015;57(1):68–74. doi: 10.32007/jfacmedbagdad.571312.
Al-Karkhi MA, Al-Ani MM, Jassim NA. Development of anti-bodies against infliximab in Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad. 2015;57(3):241-243. doi: 10.32007/jfacmedbagdad.573372.
Qaisar F, Masood A, Ujala S. Frequency of positive anti-CCP antibodies in rheumatoid arthritis patients with negative rheumatoid factor. J Islamabad Med Dental Coll. 2024;12(4):242–247. doi: 10.35787/jimdc.v12i4.665.
Abdulameer A, Mohammed KIA, Alosami MH. A comparative study of serum amyloid A2 with Anti-cyclic Citrullinated Peptide antibody in the prognosis of a Group of Rheumatoid arthritis patients in Iraq. J Fac Med Baghdad. 2022;64(3):153–158. doi: 10.32007/jfacmedbagdad.6431947.
Zhou P, Deng B, Wu M, Ding F, Wang L. Interleukin-27 ameliorates renal ischemia-reperfusion injury through signal transducers and activators of transcription 3 signaling pathway. Kidney Blood Press Res. 2019;44(6):1453-1464. doi: 10.1159/000503923.
Xu WD, Wang DC, Zhao M, Huang AF. An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases. Front Immunol. 2024;15. doi: 10.3389/fimmu.2024.1366377.
Zhao M, Zheng Z, Zhang P, Xu Y, Zhang J, Peng S, et al. IL-30 protects against sepsis-induced myocardial dysfunction by inhibiting pro-inflammatory macrophage polarization and pyroptosis. iScience. 2023;26(9):1-16. doi: 10.1016/j.isci.2023.107544.
Omar NS, Long X, Xian J, Afewerky HK, Hussain SG, Peng X. Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study. J Int Med Res. 2021;49(4):1-9. doi: 10.1177/03000605211004039.
Zou R, Huang X, Xu P. The study of gp130/the inflammatory factors regulating osteoclast differentiation in rheumatoid arthritis. Biochem Biophys Rep. 2021;26:100934. doi: 10.1016/j.bbrep.2021.100934.
Qi J, Liu J, Zhao X, Huang H, Tang Y, Li X. IL-27 enhances peripheral B cell glycolysis of rheumatoid arthritis patients via activating mTOR signaling. Int Immunopharmacol. 2023;121:110532. doi: 10.1016/j.intimp.2023.110532.
Abdul-Qahar ZH, Mahmood HG, Rasheed MK. Measurement of anti-cyclic citrullinated peptide, leptin hormone, and lipoprotein (a) in Iraqi female patients with rheumatoid arthritis. J Fac Med Baghdad. 2014;56(3):305–307. doi: 10.32007/jfacmedbagdad.563507.
Alwan I, Ghali K. The Correlation between ACCP with developing, progression and activity of rheumatoid Arthritis. Annals of RSCB. 2021;25(4):408–418.
Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, et al. B Cells in rheumatoid arthritis:Pathogenic mechanisms and treatment Prospects. Front Immunol. 2021;12. doi: 10.3389/fimmu.2021.750753.
Wong CK, Chen DP, Tam LS, Li EK, Yin YB, Lam CWK. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R129. doi: 10.1186/ar3067.
Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohnʼs disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11(1):16–23. doi: 10.1097/00054725-200501000-00003.
Tang Y, Bai Z, Qi J, Lu Z, Ahmad N, Wang G, et al. Altered peripheral B lymphocyte homeostasis and functions mediated by IL‐27 via activating the mammalian target of rapamycin signaling pathway in patients with rheumatoid arthritis. Clin Exp Immunol. 2021;206(3):354–365. doi: 10.1111/cei.13663.
Lalive PH, Kreutzfeldt M, Devergne O, Metz I, Bruck W, Merkler D, et al. Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients. Journal of Neuroinflammation. 2017;14(1). doi: 10.1186/s12974-017-0919-1.
Gholijani N, Daryabor G, Kalantar K, Yazdani MR, Shenavandeh S, Zahed M, et al. Interleukin-27 gene variant rs153109 is associated with enhanced cytokine serum levels and susceptibility to Behçet’s disease in the Iranian population. Eur Cytokine Netw. 2020;31(4):140–146. doi: 10.1684/ecn.2020.0458.
Tanida S, Yoshitomi H, Ishikawa M, Kasahara T, Murata K, Shibuya H, et al. IL-27-producing CD14+ cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration. Cytokine. 2011;55(2):237–244. doi: 10.1016/j.cyto.2011.04.020.
Villarino AV, Larkin J, Saris CJM, Caton AJ, Lucas S, Wong T, et al. Positive and Negative Regulation of the IL-27 Receptor during Lymphoid Cell Activation. J Immunol. 2005;174(12):7684–7691. doi: 10.4049/jimmunol.174.12.7684.
Mei Y, Lv Z, Xiong L, Zhang H, Yin N, Qi H. The dual role of IL-27 in CD4+T cells. Mol Immunol. 2021;138:172–180. doi: 10.1016/j.molimm.2021.08.001.
Han L, Chen Z, Yu K, Yan J, Li T, Ba X, et al. Interleukin 27 Signaling in rheumatoid arthritis patients: good or evil? Front Immunol. 2022;12. doi: 10.3389/fimmu.2021.787252.
Petes C, Mariani MK, Yang Y, Grandvaux N, Gee K. Interleukin (IL)-6 inhibits IL-27- and IL-30-Mediated inflammatory responses in human monocytes. Front Immunol. 2018;9:256. doi: 10.3389/fimmu.2018.00256.
Hanoodi M, Mittal M. Methotrexate. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556114
Pan A, Gerriets V. Etanercept. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545252
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
